Tenaya Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$93.3M | -$115.9M | -$131.2M | -$125.6M | -$72.8M |
| Operating expenses | $93.3M | $115.9M | $131.2M | $125.6M | $72.8M |
| Cash from operations | -$68.3M | -$90.5M | -$102.1M | -$104.4M | -$60.8M |
| Capital expenditure | $618,000 | $1.0M | $1.2M | $20.6M | $25.1M |
| Free cash flow | -$68.9M | -$91.5M | -$103.3M | -$125.1M | -$85.9M |
| Share repurchases | — | — | — | — | $13,000 |
| Total assets | $146.9M | $119.9M | $170.5M | $278.9M | $314.2M |
| Total liabilities | $23.7M | $27.1M | $31.1M | $35.6M | $35.7M |
Shares outstanding 217.0M · Free float 74.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.